283 related articles for article (PubMed ID: 32663622)
21. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
Popkova T; Hajek R; Jelinek T
Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
24. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
[TBL] [Abstract][Full Text] [Related]
25. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
[TBL] [Abstract][Full Text] [Related]
26. The ultrastructural basis of renal pathology in monoclonal gammopathies.
Santostefano M; Zanchelli F; Zaccaria A; Poletti G; Fusaroli M
J Nephrol; 2005; 18(6):659-75. PubMed ID: 16358223
[TBL] [Abstract][Full Text] [Related]
27. Emerging drugs for the treatment of light chain amyloidosis.
Chakraborty R; Lentzsch S
Expert Opin Emerg Drugs; 2020 Sep; 25(3):299-317. PubMed ID: 32731778
[TBL] [Abstract][Full Text] [Related]
28. Kidney and liver involvement in monoclonal light chain disorders.
Pozzi C; Locatelli F
Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
[TBL] [Abstract][Full Text] [Related]
29. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
30. [AL amyloidosis, from diagnosis to treatment].
Villesuzanne C; Jaccard A; Nicol M
Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
[TBL] [Abstract][Full Text] [Related]
31. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
32. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
33. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
[No Abstract] [Full Text] [Related]
34. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
35. Managing systemic light-chain amyloidosis.
Comenzo RL
J Natl Compr Canc Netw; 2007 Feb; 5(2):179-87. PubMed ID: 17335687
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
37. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
38. Association of systemic light-chain deposition disease and amyloidosis: a report of three patients with renal involvement.
Jacquot C; Saint-Andre JP; Touchard G; Nochy D; D'Auzac de Lamartinie C; Oriol R; Druet P; Bariety J
Clin Nephrol; 1985 Aug; 24(2):93-8. PubMed ID: 3930115
[TBL] [Abstract][Full Text] [Related]
39. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias.
Alexander KM; Evangelisti A; Witteles RM
Cardiol Clin; 2019 Nov; 37(4):487-495. PubMed ID: 31587789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
